financeMarketWatch
This GLP-1 drug helped people maintain their weight loss in a clinical trial — even for those taking it once a month
September 22, 2026
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock soared.
GN Media aggregates headlines — read the full story on MarketWatch.
Read full story on MarketWatch
